{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:23:26Z","timestamp":1789676606112,"version":"4.0.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Bari Aldo Moro"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In 1997, the monoclonal antibody A4.6.1 was humanized to create Bevacizumab (Avastin, Genentech), an antibody suitable for clinical trials. In February 2004, Bevacizumab was approved in a randomized double-blind phase III study in which was administered in combination with bolus IFL (irinotecan, 5FU, leucovorin) chemotherapy as first-line therapy for previous untreated metastatic colorectal cancer. In 2020, the EMA approved the first biosimilar of Bevacizumab for the treatment of multiple types of cancer. The administration of Bevacizumab became popular among ophthalmologists for different ocular diseases. However, in most cases of cancers, including breast, melanoma, pancreatic and prostate cancer, Bevacizumab failed to increase survival. Despite impressive performances in animal models, however, inhibitors are not performing nearly as well in humans. The limitations of applying Bevacizumab are attributed to drug resistance, metastasis promotion and reduced delivery of chemotherapeutic agents, resulting from the dramatic decrease in tumor vasculature.<\/jats:p>","DOI":"10.1007\/s10238-025-01857-y","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T09:32:10Z","timestamp":1760693530000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The discovery of Bevacizumab. An historical reappraisal"],"prefix":"10.1007","volume":"25","author":[{"given":"Domenico","family":"Ribatti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"1857_CR1","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197108122850711","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182\u20136.","journal-title":"N Engl J Med"},{"key":"1857_CR2","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/0006-291X(89)92678-8","volume":"161","author":"N Ferrara","year":"1989","unstructured":"Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989;161:851\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"1857_CR3","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1126\/science.2479986","volume":"246","author":"DW Leung","year":"1989","unstructured":"Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306\u20139.","journal-title":"Science"},{"key":"1857_CR4","doi-asserted-by":"crossref","first-page":"20017","DOI":"10.1016\/S0021-9258(19)47212-8","volume":"264","author":"DT Connolly","year":"1989","unstructured":"Connolly DT, Olander JV, Heuvelman D, Nelson R, Monsell R, Siegel N, et al. Human vascular permeability factor. Isolation from U937 cells. J Biol Chem. 1989;264:20017\u201324.","journal-title":"J Biol Chem"},{"key":"1857_CR5","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.2479987","volume":"246","author":"PJ Keck","year":"1989","unstructured":"Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J, et al. Vascular permeability factor, an endothelial mitogen related to PDGF. Science. 1989;246:1309\u201312.","journal-title":"Science"},{"key":"1857_CR6","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/362841a0","volume":"362","author":"KJ Kim","year":"1993","unstructured":"Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature. 1993;362:841\u20134.","journal-title":"Nature"},{"key":"1857_CR7","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1172\/JCI117857","volume":"95","author":"RS Warren","year":"1995","unstructured":"Warren RS, Yuan H, Matli MR, Gillett NA, Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest. 1995;95:1789\u201397.","journal-title":"J Clin Invest"},{"key":"1857_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1097-0045(19980401)35:1<1::AID-PROS1>3.0.CO;2-O","volume":"35","author":"P Borgstrom","year":"1998","unstructured":"Borgstrom P, Bourdon MA, Hillan KJ, Sriramarao P, Ferrara N. Neutralizing anti-vascular endothelial growth factor antibody completely inhibitsangiogenesis and growth of human prostate carcinoma microtumors in vivo. Prostate. 1998;35:1\u201310.","journal-title":"Prostate"},{"issue":"1999","key":"1857_CR9","first-page":"4203","volume":"19","author":"P Borgstrom","year":"1999","unstructured":"Borgstrom P, Gold DP, Hillan KJ, Ferrara N. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing antibody and doxorubicin. Anticancer Res. 1999;19(1999):4203\u201314.","journal-title":"Anticancer Res"},{"key":"1857_CR10","first-page":"4032","volume":"56","author":"P Borgstrom","year":"1996","unstructured":"Borgstrom P, Hillan KJ, Sriramarao P, Ferrara N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concept of angiostatic therapy from intravital videomicroscopy. Cancer Res. 1996;56:4032\u20139.","journal-title":"Cancer Res"},{"key":"1857_CR11","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S0002-9440(10)65669-6","volume":"153","author":"S Mesiano","year":"1998","unstructured":"Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascite formation by immunoneutralization. Am J Pathol. 1998;153:1249\u201356.","journal-title":"Am J Pathol"},{"key":"1857_CR12","doi-asserted-by":"crossref","first-page":"14765","DOI":"10.1073\/pnas.93.25.14765","volume":"93","author":"F Yuan","year":"1996","unstructured":"Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established xenografts induced by an anti-vascular endothelial growth factor\/vascular permeability factor antibody. Proc Natl Acad Sci U S A. 1996;93:14765\u201370.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1857_CR13","first-page":"4593","volume":"57","author":"LG Presta","year":"1997","unstructured":"Presta LG, Chen H, O\u2019Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Ferrara N., Humanization of anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593\u20139.","journal-title":"Cancer Res"},{"key":"1857_CR14","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1200\/JCO.2001.19.3.851","volume":"19","author":"K Margolin","year":"2001","unstructured":"Margolin K, Gordon MS, Holmgren E, Gaudreault J, Novotny W, Fyfe G, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol. 2001;19:851\u20136.","journal-title":"J Clin Oncol"},{"key":"1857_CR15","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2001.19.3.843","volume":"19","author":"MS Gordon","year":"2001","unstructured":"Gordon MS, Margolin K, Talpaz M, Sledge GW Jr., Holmgren E, Benjamin R, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001;19:843\u201350.","journal-title":"J Clin Oncol"},{"key":"1857_CR16","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1200\/JCO.2003.10.066","volume":"21","author":"F Kabbinavar","year":"2003","unstructured":"Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Npvotny WF, Lieberman G, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)\/leucovorin (LV) with FU\/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60\u20135.","journal-title":"J Clin Oncol"},{"key":"1857_CR17","first-page":"2884","volume":"22","author":"DH Johnson","year":"2004","unstructured":"Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, et al. Randomized phase II trial comparing bevacizumab pls carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:2884\u20132191.","journal-title":"J Clin Oncol"},{"key":"1857_CR18","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","volume":"349","author":"JC Yang","year":"2003","unstructured":"Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Tapalian SL, et al. A randomized trial of bevacizumab, an anti-VEGF antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427\u201334.","journal-title":"N Engl J Med"},{"key":"1857_CR19","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth H, Helm W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovarin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335\u201342.","journal-title":"N Engl J Med"},{"key":"1857_CR20","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1053\/j.seminoncol.2006.08.001","volume":"33","author":"H Horwitz","year":"2006","unstructured":"Horwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol. 2006;33:S26\u201334.","journal-title":"Semin Oncol"},{"key":"1857_CR21","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1634\/theoncologist.12-3-356","volume":"12","author":"MH Cohen","year":"2007","unstructured":"Cohen MH, Gootenberg J, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. Oncologist. 2007;12:356\u201361.","journal-title":"Oncologist"},{"key":"1857_CR22","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1097\/JTO.0b013e3181da36f4","volume":"5","author":"A Sandler","year":"2010","unstructured":"Sandler A, Yi J, Dahlberg S, Kolb MM, Wang L, Hambleton J, et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel\/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol. 2010;5:1416\u201323.","journal-title":"J Thorac Oncol"},{"key":"1857_CR23","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666\u201376.","journal-title":"N Engl J Med"},{"issue":"2010","key":"1857_CR24","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","volume":"28","author":"DW Miles","year":"2010","unstructured":"Miles DW, Chan A, Dirix LY, Cortes J, Pivot X, Tomczak P, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28(2010):3239\u201347.","journal-title":"J Clin Oncol"},{"key":"1857_CR25","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1200\/JCO.2010.34.1255","volume":"29","author":"AM Brufsky","year":"2011","unstructured":"Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O\u2019Neill V, et al. RIBBON-2: a randomized, double blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2011;29:4286\u201393.","journal-title":"J Clin Oncol"},{"key":"1857_CR26","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1200\/JCO.2010.28.0982","volume":"29","author":"NJ Robert","year":"2011","unstructured":"Robert NJ, Dieras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011;29:1252\u201360.","journal-title":"J Clin Oncol"},{"key":"1857_CR27","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","volume":"370","author":"B Escudier","year":"2007","unstructured":"Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103\u201311.","journal-title":"Lancet"},{"key":"1857_CR28","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","volume":"390","author":"KS Tewari","year":"2017","unstructured":"Tewari KS, Sill MW, Penson RT, Huang H, Ramondetta LM, Landrum LM, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017;390:1654\u201363.","journal-title":"Lancet"},{"key":"1857_CR29","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A Phase 3 Trial of Bevacizumab in Ovarian Cancer. N Engl J Med. 2011;365:2484\u201396.","journal-title":"N Engl J Med"},{"key":"1857_CR30","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello M-G, Husain A, et al. A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039\u201345.","journal-title":"J Clin Oncol"},{"key":"1857_CR31","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","volume":"27","author":"HS Friedman","year":"2009","unstructured":"Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27:4733\u201340.","journal-title":"J Clin Oncol"},{"key":"1857_CR32","doi-asserted-by":"crossref","first-page":"XVII","DOI":"10.6004\/jnccn.2011.0089","volume":"9","author":"NCCN Breast Cancer Panel","year":"2011","unstructured":"NCCN Breast Cancer Panel. Reaffirms current position and recommendation regarding the use of bevacizumab in metastatic breast cancer. J Natl Compr Canc Netw. 2011;9:XVII.","journal-title":"J Natl Compr Canc Netw"},{"key":"1857_CR33","unstructured":"NCCN Clinical Practice Guidelines in Oncology for Non-Small Cell Lung Cancer. National Comprehens, Cancer Network, Inc. 2019."},{"key":"1857_CR34","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.6004\/jnccn.2014.0118","volume":"12","author":"B Nabors","year":"2014","unstructured":"Nabors B. The role of Bevacizumab in glioblastoma. J Natl Compr Canc Netw. 2014;12:1201\u20132.","journal-title":"J Natl Compr Canc Netw"},{"key":"1857_CR35","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","volume":"370","author":"KS Tewari","year":"2014","unstructured":"Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370:734\u201343.","journal-title":"N Engl J Med"},{"key":"1857_CR36","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1200\/JCO.2013.51.4240","volume":"32","author":"MR Stockler","year":"2014","unstructured":"Stockler MR, Hilpert F, Friedlander M, King MT, Wenzel L, Lee CK, et al. Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer. J Clin Oncol. 2014;32:1309\u201316.","journal-title":"J Clin Oncol"},{"key":"1857_CR37","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s40264-017-0596-0","volume":"41","author":"T Kato","year":"2018","unstructured":"Kato T, Seto T, Nishio M, Goto K, Yamamoto N, Okamoto I, et al. Erlotinib plus bevacizumab phase ll study in patients with advanced non-small-cell lung cancer (JO25567): updated safety results. Drug Saf. 2018;41:229\u201337.","journal-title":"Drug Saf"},{"key":"1857_CR38","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","volume":"14","author":"J Bennouna","year":"2013","unstructured":"Bennouna J, Sastre J, Arnold D, \u00d6sterlund P, Greil R, Van Cutsem E, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): randomised phase 3 trial. Lancet Oncol. 2013;14:29\u201337.","journal-title":"Lancet Oncol"},{"key":"1857_CR39","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, et al. IMbrave050 investigators, atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre phase 3 trial. Lancet. 2023;402:1835\u201347.","journal-title":"Lancet"},{"key":"1857_CR40","unstructured":"NICE. Ovarian cancer (advanced): bevacizumab 7.5 mg\/kg in combination with paclitaxel and carboplatin for first-line treatment.https:\/\/www.nice.org.uk\/guidance\/esuom21."},{"issue":"8","key":"1857_CR41","first-page":"403","volume":"2012","author":"E Christina","year":"2012","unstructured":"Christina E, Stevenson NM, Ramachandran S, Yamada A, Bear HD, Takabe K. Bevacizumab and breast cancer: what does the future hold? Future Oncol. 2012;2012(8):403\u201314.","journal-title":"Future Oncol"},{"issue":"15","key":"1857_CR42","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(14)70110-X","volume":"2014","author":"PG Corrie","year":"2014","unstructured":"Corrie PG, Marshall A, Dunn JA, Middleton MR, Nathan PD, Gore M, et al. Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. The Lancet Oncol. 2014;2014(15):620\u201330.","journal-title":"The Lancet Oncol"},{"key":"1857_CR43","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.18632\/oncotarget.2972","volume":"6","author":"GM Heestand","year":"2015","unstructured":"Heestand GM, Kurzrock R. Molecular landscape of pancreatic cancer: implications for current clinical trials. Oncotarget. 2015;6:4453\u2013561.","journal-title":"Oncotarget"},{"key":"1857_CR44","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1200\/JCO.2011.39.4767","volume":"30","author":"WK Kelly","year":"2012","unstructured":"Kelly WK, Halabi S, Carducci M, George D, Small EJ, Mahoney JF, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012;30:1534\u201340.","journal-title":"J Clin Oncol"},{"key":"1857_CR45","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.1200\/JCO.2005.05.112","volume":"23","author":"FF Kabbinavar","year":"2005","unstructured":"Kabbinavar FF, Schulz J, McCleod M, Patel T, Hamm JT, Hecht JR, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005;23:3697\u2013705.","journal-title":"J Clin Oncol"},{"key":"1857_CR46","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","volume":"26","author":"LB Saltz","year":"2008","unstructured":"Saltz LB, Clarke S, D\u00edaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013\u20139.","journal-title":"J Clin Oncol"},{"key":"1857_CR47","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1200\/JCO.2009.27.7723","volume":"28","author":"NC Tebbutt","year":"2010","unstructured":"Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, van Hazel GA, et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group randomized phase III MAX study. J Clin Oncol. 2010;28:3191\u20138.","journal-title":"J Clin Oncol"},{"key":"1857_CR48","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfister J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of Bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484\u201396.","journal-title":"N Engl J Med"},{"key":"1857_CR49","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","volume":"16","author":"AM Oza","year":"2015","unstructured":"Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16:928\u201336.","journal-title":"Lancet Oncol"},{"key":"1857_CR50","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","volume":"139","author":"C Aghajanian","year":"2015","unstructured":"Aghajanian C, Goff B, Nycum LR, Wang YV, Husain A, Blank SV. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2015;139:10\u20136.","journal-title":"Gynecol Oncol"},{"key":"1857_CR51","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. Oceans: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039\u201345.","journal-title":"J Clin Oncol"},{"key":"1857_CR52","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","volume":"37","author":"KS Tewari","year":"2019","unstructured":"Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, et al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J Clin Oncol. 2019;37:2317\u201328.","journal-title":"J Clin Oncol"},{"key":"1857_CR53","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1200\/JCO.2009.26.7849","volume":"28","author":"B Escudier","year":"2010","unstructured":"Escudier B, Bellmunt J, N\u00e9grier S, Bajetta E, Melichar B, Bracarda S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28:2144\u201350.","journal-title":"J Clin Oncol"},{"key":"1857_CR54","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamaoncol.2021.5981","volume":"8","author":"RJ Motzer","year":"2022","unstructured":"Motzer RJ, Powles T, Atkins MB, Escudier B, McDermott DF, Alekseev BY, et al. Final overall survival and molecular analysis in IMmotion151, a phase 3 trial comparing atezolizumab plus bevacizumab vs sunitinib in patients with previously untreated metastatic renal cell carcinoma. JAMA Oncol. 2022;8:275\u201380.","journal-title":"JAMA Oncol"},{"key":"1857_CR55","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1200\/JCO.2012.46.2762","volume":"31","author":"D Lambrechts","year":"2013","unstructured":"Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol. 2013;31:1219\u201330.","journal-title":"J Clin Oncol"},{"key":"1857_CR56","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1172\/JCI24612","volume":"116","author":"MR Mancuso","year":"2006","unstructured":"Mancuso MR, Davis R, Norberg SM, O\u2019Brien S, Sennino B, Nakahara T, et al. Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest. 2006;116:2610\u201321.","journal-title":"J Clin Invest"},{"key":"1857_CR57","doi-asserted-by":"crossref","first-page":"5326","DOI":"10.1200\/JCO.2008.16.3212","volume":"26","author":"A Grothey","year":"2008","unstructured":"Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol. 2008;26:5326\u201334.","journal-title":"J Clin Oncol"},{"key":"1857_CR58","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2022.100849","volume":"64","author":"M Huang","year":"2022","unstructured":"Huang M, Lin Y, Wang C, Deng L, Chen M, Assaraf YG, et al. New insights into antiangiogenic therapy resistance in cancer: mechanisms and therapeutic aspects. Drug Resist Updat. 2022;64:100849.","journal-title":"Drug Resist Updat"},{"key":"1857_CR59","doi-asserted-by":"crossref","first-page":"102017","DOI":"10.1016\/j.ctrv.2020.102017","volume":"86","author":"G Garcia","year":"2020","unstructured":"Garcia G, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo D, et al. Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020;86:102017.","journal-title":"Cancer Treat Rev"},{"key":"1857_CR60","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ccr.2011.11.023","volume":"21","author":"AA Van der Veldt","year":"2012","unstructured":"Van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell. 2012;21:82\u201391.","journal-title":"Cancer Cell"},{"key":"1857_CR61","first-page":"937","volume":"30","author":"T Karashima","year":"2007","unstructured":"Karashima T, Inoue K, Fukata S, Iiyama T, Kurabayashi A, Kawada C, et al. Blockade of the vascular endothelial growth factor-receptor 2 pathway inhibits the growth of human renal cell carcinoma, RBM1-IT4, in the kidney but not in the bone of nude mice. Int J Oncol. 2007;30:937\u201345.","journal-title":"Int J Oncol"},{"key":"1857_CR62","doi-asserted-by":"crossref","first-page":"1323350","DOI":"10.3389\/fonc.2023.1323350","volume":"13","author":"D Ribatti","year":"2023","unstructured":"Ribatti D, Annese T, Tamma R. Vascular co-option in resistance to anti-angiogenic therapy. Front Oncol. 2023;13:1323350.","journal-title":"Front Oncol"},{"key":"1857_CR63","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrd3455","volume":"10","author":"P Carmeliet","year":"2011","unstructured":"Carmeliet P, Jain RK. Principle and mechanisms of vessel normalization for cancer and other angiogenic diseases. Drug Discov. 2011;10:417\u201327.","journal-title":"Drug Discov"},{"key":"1857_CR64","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","volume":"26","author":"RK Jain","year":"2014","unstructured":"Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014;26:605\u201322.","journal-title":"Cancer Cell"},{"issue":"9\u201310","key":"1857_CR65","first-page":"599","volume":"70","author":"LY Joanne","year":"2002","unstructured":"Joanne LY, Kerbel RS, Coomber BL. A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance. Differentiation. 2002;70(9\u201310):599\u2013609.","journal-title":"Differentiation"},{"key":"1857_CR66","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.drup.2004.09.001","volume":"7","author":"JG Bender","year":"2004","unstructured":"Bender JG, Cooney EM, Kandel JJ, Yamashiro DJ. Vascular remodelling and clinical resistance to antiangiogenic cancer therapy. Drug Resist Update. 2004;7:289\u2013300.","journal-title":"Drug Resist Update"},{"key":"1857_CR67","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/1947601909356574","volume":"1","author":"S Loges","year":"2010","unstructured":"Loges S, Schmidt T, Carmeliet P. Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Genes Cancer. 2010;1:12\u201325.","journal-title":"Genes Cancer"},{"key":"1857_CR68","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.1158\/1078-0432.CCR-17-0874","volume":"23","author":"S Ueda","year":"2017","unstructured":"Ueda S, Saeki T, Osaki A, Yamane T, Kuji I. Bevacizumab induces acute hypoxia and cancer progression in patients with refractory breast cancer: multimodal functional imaging and multiplex cytokine analysis. Clin Cancer Res. 2017;23:5769\u201378.","journal-title":"Clin Cancer Res"},{"issue":"22","key":"1857_CR69","doi-asserted-by":"crossref","first-page":"8249","DOI":"10.1158\/0008-5472.CAN-04-1567","volume":"64","author":"K Hida","year":"2004","unstructured":"Hida K, Hida Y, Amin DN, Flint AF, Panigrahy D, Morton CC, et al. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer res. 2004;64(22):8249\u201355.","journal-title":"Cancer res"},{"key":"1857_CR70","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-022-00838-y","volume":"20","author":"MJ Ansari","year":"2022","unstructured":"Ansari MJ, Bokov D, Markov A, Turki Jalil A, Shalaby MN, Suksatan W, et al. Cancer combination therapies by angiogenesis inhibitors; a comprehensive review. Cell Commun Signal. 2022;20:49.","journal-title":"Cell Commun Signal"},{"key":"1857_CR71","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/PPO.0000000000000327","volume":"24","author":"D Chen","year":"2018","unstructured":"Chen D, Horwitz H. Combinations of bevacizumab with cancer immunotherapy. Cancer J. 2018;24:193\u2013204.","journal-title":"Cancer J"},{"key":"1857_CR72","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/2326-6066.CIR-14-0053","volume":"2","author":"FS Hodi","year":"2014","unstructured":"Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res. 2014;2:632\u201342.","journal-title":"Cancer Immunol Res"},{"key":"1857_CR73","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1158\/1078-0432.CCR-20-3407","volume":"27","author":"SJ Casak","year":"2021","unstructured":"Casak SJ, Donoghue M, Fashoyin-Aje L, Jiang X, Rodriguez L, Shen YL, et al. FDA approval summary atezolizumab plus bevacizumab for the treatment of patients with advanced unresectable or metastatic hepatocellular carcinoma. Clin Cancer Res. 2021;27:1836\u201341.","journal-title":"Clin Cancer Res"},{"key":"1857_CR74","volume":"13","author":"AT Ng","year":"2024","unstructured":"Ng AT, Steve T, Jamouss KT, Arham A, Kawtharani S, Assi HI. The challenges and clinical landscape of glioblastoma immunotherapy. CNS Oncol. 2024;13:2415878.","journal-title":"CNS Oncol"},{"key":"1857_CR75","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s11060-017-2466-0","volume":"133","author":"MC Chamberlain","year":"2017","unstructured":"Chamberlain MC, Kim BT. Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series. J Neurooncol. 2017;133:561\u20139.","journal-title":"J Neurooncol"},{"key":"1857_CR76","doi-asserted-by":"crossref","first-page":"778978","DOI":"10.3389\/fimmu.2021.778978","volume":"12","author":"X Xiaopei Cui","year":"2021","unstructured":"Xiaopei Cui X, Huifeng Jia H, Xin H, Zhang L, Chen S, Xia S, et al. A novel bispecific antibody targeting PD-L1 and VEGF with combined anti-tumor activities. Front Immunol. 2021;12:778978.","journal-title":"Front Immunol"},{"key":"1857_CR77","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211072703","volume":"14","author":"JE Riedesser","year":"2022","unstructured":"Riedesser JE, Ebert MP, Betge J. Precision medicine for metastatic colorectal cancer in clinical practice. Ther Adv Med Oncol. 2022;14:17588359211072703.","journal-title":"Ther Adv Med Oncol"},{"key":"1857_CR78","doi-asserted-by":"crossref","first-page":"709","DOI":"10.5009\/gnl240085","volume":"18","author":"BG Song","year":"2024","unstructured":"Song BG, Goh MJ, Kang W, Sinn DH, Gwak GY, Choi MS, et al. Analysis of factors predicting the real-world efficacy of atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma. Gut Liver. 2024;18:709\u201318.","journal-title":"Gut Liver"},{"key":"1857_CR79","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.soncn.2014.03.003","volume":"30","author":"L Adams","year":"2014","unstructured":"Adams L. Precision medicine in oncology standard of care. Semin Oncol Nurs. 2014;30:100\u20138.","journal-title":"Semin Oncol Nurs"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01857-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01857-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01857-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:53:09Z","timestamp":1764917589000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01857-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1857"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01857-y","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"315"}}